Ērika Bitiņa-Barlote
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ērika Bitiņa-Barlote has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Dmitrijs Bliznuks
Institute of Applied Computer Systems, Riga Technical University, LV-1048 Riga, Latvia
1 shared publication - Edvins Miklasevics
Faculty of Medicine, Riga Stradins University, LV-1007 Riga, Latvia
1 shared publication - Egils Vjaters
Institute of Oncology and Molecular Genetics, Riga Stradins University, LV-1002 Riga, Latvia
1 shared publication - Janis Gardovskis
Department of Surgery, Riga Stradins University, Dzirciema Street 16, LV-1007 Riga, Latvia
1 shared publication - Juris Plonis
Institute of Oncology and Molecular Genetics, Riga Stradins University, LV-1002 Riga, Latvia
1 shared publication - Mihails Šatcs
Institute of Oncology and Molecular Genetics, Riga Stradins University, Pilsonu Street 13, Block 13, LV-1002 Riga, Latvia
1 shared publication
Latest Publications
- Open Access
- 18 February 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (4) , 492
Liquid Biopsy Based Bladder Cancer Diagnostic by Machine Learning
Background/Objectives: The timely diagnostics of bladder cancer is still a challenge in clinical settings. The reliability of conventional testing methods does not reach desirable accuracy and sensitivity, and it has an invasive nature. The present study examines the application of machine learning to improve bladder cancer diagnostics by integrating miRNA expression levels, demographic routine laboratory test results, and clinical data. We proposed that merging these datasets would enhance diagnostic accuracy. Methods: This study combined molecular biology methods for liquid biopsy, routine clinical data, and application of machine learning approach for the acquired data analysis. We evaluated urinary exosome miRNA expression data in combination with patient test results, as well as clinical and demographic data using three machine learning models: Random Forest, SVM, and XGBoost classifiers. Results: Based solely on miRNA data, the SVM model achieved an ROC curve area of 0.75. Patient analysis’ clinical and demographic data obtained ROC curve area of 0.80. Combining both data types enhanced performance, resulting in an F1 score of 0.79 and an ROC of 0.85. The feature importance analysis identified key predictors, including erythrocytes in urine, age, and several miRNAs. Conclusions: Our findings indicate the potential of a multi-modal approach to improve the accuracy of bladder cancer diagnosis in a non-invasive manner.
- 18 February 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (4) , 492
Open AccessLiquid Biopsy Based Bladder Cancer Diagnostic by Machine Learning
Background/Objectives: The timely diagnostics of bladder cancer is still a challenge in clinical settings. The reliability of conventional testing methods does not reach desirable accuracy and sensitivity, and it has an invasive nature. The present study examines the application of machine learning to improve bladder cancer diagnostics by integrating miRNA expression levels, demographic routine laboratory test results, and clinical data. We proposed that merging these datasets would enhance diagnostic accuracy. Methods: This study combined molecular biology methods for liquid biopsy, routine clinical data, and application of machine learning approach for the acquired data analysis. We evaluated urinary exosome miRNA expression data in combination with patient test results, as well as clinical and demographic data using three machine learning models: Random Forest, SVM, and XGBoost classifiers. Results: Based solely on miRNA data, the SVM model achieved an ROC curve area of 0.75. Patient analysis’ clinical and demographic data obtained ROC curve area of 0.80. Combining both data types enhanced performance, resulting in an F1 score of 0.79 and an ROC of 0.85. The feature importance analysis identified key predictors, including erythrocytes in urine, age, and several miRNAs. Conclusions: Our findings indicate the potential of a multi-modal approach to improve the accuracy of bladder cancer diagnosis in a non-invasive manner.